Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab
Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Treatment cessation due to a dry retina has not been systematically addressed in diabetic macular edema (DME). In three out of four patients receiving 6 mg of brolucizumab in the KITE study, treatment was terminated after the study ended.
The KITE study was a double-masked, multicenter, active-controlled, randomized trial (NCT03481660) in DME pa...
Alternative Titles
Full title
Sustained Disease Control in DME Patients upon Treatment Cessation with Brolucizumab
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10971211
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10971211
Other Identifiers
ISSN
2077-0383
E-ISSN
2077-0383
DOI
10.3390/jcm13061534
